Latest News

• 
  All Medical News

  Real-world data shows details beyond the clinical trials

  Written by Karen Ramirez | 21 Feb 2018

  Professor Paul G. Richardson MD (R.J. Corman Professor, Medicine, Harvard Medical School, Boston, USA) and Dr Karthik Ramasamy (Oxford Oncology and Haematology Centre) discuss important learnings from real-world… read more.

• 
  All Medical News

  More ASH Highlights (Myeloma)

  Written by Karen Ramirez | 21 Feb 2018

  There were lots of updates from various studies in myeloma at ASH 2017. Above, Professor Sagar Lonial (Emory University School of Medicine, Atlanta, GA) discusses data presented showing… read more.

• 
  All Medical News

  UK research in the spotlight at ASH

  Written by Karen Ramirez | 16 Feb 2018

  The chair of the UK Myeloma Research Alliance, Professor Gordon Cook (Leeds Teaching Hospitals Trust) highlights some of the data presented from the UK, including data from the… read more.

• 
  All Medical News

  ASH Highlights (Myeloma)

  Written by Karen Ramirez | 13 Feb 2018

  As usual, there was a lot of new data in at ASH 2017 in myeloma. Above Professor S Vincent Rajkumar (Mayo Clinic, Rochester, USA) gives a great overview of… read more.

• 
  All Medical News

  ECCO 2018: Novel treatments in IBD

  Written by Karen Ramirez | 11 Feb 2018

  The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.

• 
  All Medical News

  New insights into HL biology

  Written by Karen Ramirez | 5 Feb 2018

  Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.

• 
  All Medical News

  Which groups benefited most from an ECHELON-1 approach?

  Written by Karen Ramirez | 5 Feb 2018

  Professor Stephen Ansell (Mayo Clinic, USA) discusses who might benefit most from A+AVD upfront in HL. Interview by Esther Drain.

• 
  All Medical News

  ASH 2017 Highlights

  Written by Karen Ramirez | 5 Feb 2018

  Professor Anas Younes (MSKCC, New York), Professor John Radford (Manchester) and Dr Graham Collins (Oxford). Interviews by Esther Drain. Once again ASH provided much food for thought and above leading experts discuss their… read more.

• 
  All Medical News

  ASH 2017: Mixed results for new NHL therapies

  Written by Alex Burton | 19 Jan 2018

  Article written by Tom Collins. Interviews by Esther Drain. Trying to usher new immunotherapies into the setting of non-Hodgkin lymphomas (NHL) has been met with mixed results, and… read more.

• 
  All Medical News

  ASH 2017: ECHELON-1: Brentuximab vedotin plus AVD in HL produces PFS improvement

  Written by Alex Burton | 19 Jan 2018

  Article written by Tom Collins. Interviews by Esther Drain. Replacing bleomycin with brentuximab vedotin (A+AVD) in the traditional regimen for previously untreated Hodgkin lymphoma patients significantly improved modified… read more.

• 
  All Medical News

  ASH 2017: Experts offer guidance on smouldering myeloma

  Written by Alex Burton | 17 Jan 2018

  Article written by Tom Collins. Interview by Esther Drain. Even as definitions of risk groups in myeloma become more sophisticated, a reasonable way to assess those patients with… read more.

• 
  All Medical News

  Hesitation still surrounds use of ‘cure’ word in MM

  Written by Karen Ramirez | 15 Jan 2018

  Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar (Mayo Clinic,… read more.